AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in Orlando, Florida.

The schedule for tivozanib poster presentations at ASCO GU is as follows:
 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (B3)
(Abstract #350) Title: Overall Survival Results from a Phase 3 Study of Tivozanib Hydrochloride vs Sorafenib in Patients with Renal Cell Carcinoma

Presenter: Robert Motzer, M.D.
 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (B7)

(Abstract #354) Title: Subgroup Analyses of a Phase 3 Trial Comparing Tivozanib Hydrochloride vs Sorafenib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma (mRCC)

Presenter: Thomas Hutson, D.O., Pharm.D.
 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (B8)
(Abstract #355) Title: Treatment Benefit of Tivozanib Hydrochloride versus Sorafenib on Health-Related Quality of Life among Patients with Advanced/Metastatic Renal Cell Carcinoma (mRCC): TIVO-1 Study Results

Presenter: David Cella, Ph.D.
 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (C1)
(Abstract #364) Title: Efficacy and Safety Data from Patients with Advanced Renal Cell Cancer Treated with Tivozanib Hydrochloride After Progression on Sorafenib

Presenter: Robert Motzer, M.D.
 

Date & Time: Saturday, February 16, 2013; 6:45-7:55am and 11:50am-1:05pm EST

Session: General Poster Session: C: Renal Cell Cancer (B14)
(Abstract #361) Title: Relationship of Hypoxia Signature with Variant Subgroup of Clear Cell Renal Cell Carcinoma (ccRCC) and its Association with Clinical Activity on Tivozanib Hydrochloride

Presenter: Murray Robinson, Ph.D.

About Kidney Cancer

Advanced RCC, or kidney cancer, is the ninth most commonly diagnosed cancer in men and women in the U.S. 1 Worldwide it is estimated that more than 250,000 people are diagnosed and more than 100,000 people die from the disease each year. 2 RCC accounts for more than 90 percent of all kidney cancers. 3 Currently available therapies provide less than one year of median progression-free survival (PFS) in treatment naive patients and are associated with significant toxicities. 4 These toxicities not only lead to high rates of dose reductions and interruptions (potentially compromising efficacy), but also can impact a patient’s quality of daily living. 5

About Tivozanib

Tivozanib is a potent, selective and long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor for which positive results from a Phase 3 clinical study in advanced RCC have been reported, and is being evaluated in other tumors.

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales